by AbbVie
with support from Lucid Group
By Amicus Therapeutics UK Ltd
by Sanofi Genzyme
with support from Health IQ, Republic M! and Havas Life Medicom
by Sanofi Genzyme
with support from Health IQ, Republic M! and Havas Life Medicom
Mucopolysaccharidosis Type I (MPS I) has an overall prevalence of 1:100,0001 meaning that any one paediatrician is unlikely to see a patient during his/her career. It is a progressive, debilitating, life- threatening disease which, if diagnosed early with a simple urine test, can be effectively managed at specialist centres to give patients better outcomes. We needed a new approach, without an in-house sales team, to raise awareness of MPS I. Analysis of RWD, conducted in line with Information Governance (IG) rules, outlined MPS I prevalence at a suitable regional level and a separate segmentation exercise provided priority lists of paediatric specialities who may potentially see MPS I children in their clinics. To execute the final part of the campaign, a third-party remote detailing agency contacted physicians, from the priority lists provided, to educate them on the condition, give information on how to test and diagnose MPS I and refer suspected cases to specialist treatment centres for follow-up and management.
1. Laraway S, Breen C, Mercer J et al Molecular Genetics and Metabolism 2013;109:315-316
Sanofi Genzyme showed real precision marketing pinpoint of understanding. They took a creative analytical approach and had real, demonstrable outcomes. We liked seeing the re-work of the data and the smart working.
Entry deadline | 27 August 2020 |
Extended entry deadline | 3 September 2020* *additional fee applies |
Judging Day | 1 October 2020 |
Company of the Year Interviews | 22 October 2020 |
PMEA Event | 25 November 2020 |